Evaluation of the Efficacy of Systemic Inflammatory Markers in Predicting Medical Treatment Failure in Patients with Tubo-Ovarian Abscess

Systemic inflammatory markers -particularly, the Systemic Immune-Inflammation Index (SII)- appear to be robust, cost-effective, and readily available tools for predicting medical treatment failure in patients with TOA. Predictive performance is enhanced when SII is interpreted in conjunction with NLR and relevant clinical history, especially prior curettage. Integrating these independent predictors into clinical decision-making may facilitate earlier identification of high-risk patients and expedite escalation to surgical intervention, thereby minimizing delays and improving patient outcomes.